Evolent Health, Inc. (EVH) has a negative trailing P/E of -0.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 18.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -196.23%, forward earnings yield 5.47%. PEG 0.27 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 40/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -4.2 | 0.03 | 0.95 | 2.62 | - |
| 2017 | -13.0 | 0.18 | 0.78 | 1.82 | - |
| 2018 | -29.3 | 1.06 | 1.35 | 2.46 | - |
| 2019 | -2.5 | -0.01 | 0.81 | 1.08 | - |
| 2020 | -4.1 | -0.66 | 2.20 | 1.47 | 1.47% |
| 2021 | -63.3 | 0.70 | 3.43 | 2.62 | 0.05% |
| 2022 | -137.3 | 3.09 | 3.06 | 1.95 | - |
| 2023 | -32.5 | -0.06 | 3.44 | 1.87 | 0.51% |
| 2024 | -20.9 | 0.57 | 1.29 | 0.51 | 1.56% |
| 2025 | -0.9 | 0.00 | 1.10 | 0.24 | 2.44% |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-3.55 | $254.19M | $-159.74M | -62.8% |
| 2017 | $-0.94 | $434.95M | $-60.67M | -13.9% |
| 2018 | $-0.68 | $627.06M | $-52.66M | -8.4% |
| 2019 | $-3.71 | $846.38M | $-305.58M | -36.1% |
| 2020 | $-3.94 | $1.02B | $-334.25M | -32.7% |
| 2021 | $-0.35 | $907.96M | $-30.28M | -3.3% |
| 2022 | $-0.20 | $1.35B | $-18.7M | -1.4% |
| 2023 | $-1.28 | $1.96B | $-113.04M | -5.8% |
| 2024 | $-0.81 | $2.55B | $-61.62M | -2.4% |
| 2025 | $-5.07 | $1.88B | $-534.51M | -28.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $0.14 | $0.12 – $0.17 | $2.49B | $2.45B – $2.53B | 8 |
| 2027 | $0.42 | $0.35 – $0.52 | $2.88B | $2.63B – $3.17B | 7 |
| 2028 | $0.57 | $0.07 – $1.01 | $3.26B | $3.26B – $3.26B | 4 |
| 2029 | $0.84 | $0.78 – $0.92 | $3.82B | $3.62B – $4.09B | 2 |
| 2030 | $1.08 | $1.01 – $1.18 | $4.4B | $4.17B – $4.71B | 2 |
